These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25632846)

  • 1. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.
    Rath T; Billmeier U; Waldner MJ; Atreya R; Neurath MF
    Arch Toxicol; 2015 Apr; 89(4):541-54. PubMed ID: 25632846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
    Neurath MF; Finotto S
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):83-9. PubMed ID: 21377916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-12-and IL-23 in health and disease.
    Croxford AL; Kulig P; Becher B
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):415-21. PubMed ID: 25130295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target.
    Allocca M; Jovani M; Fiorino G; Schreiber S; Danese S
    Curr Drug Targets; 2013 Nov; 14(12):1508-21. PubMed ID: 24102406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
    Waldner MJ; Neurath MF
    Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3 and its activators in intestinal defense and mucosal homeostasis.
    Hruz P; Dann SM; Eckmann L
    Curr Opin Gastroenterol; 2010 Mar; 26(2):109-15. PubMed ID: 20040863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer.
    Li Y; de Haar C; Peppelenbosch MP; van der Woude CJ
    Cytokine Growth Factor Rev; 2012 Jun; 23(3):127-38. PubMed ID: 22591635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-27: a double agent in the IL-6 family.
    Jones GW; Hill DG; Cardus A; Jones SA
    Clin Exp Immunol; 2018 Jul; 193(1):37-46. PubMed ID: 29437229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders.
    Vanaudenaerde BM; Verleden SE; Vos R; De Vleeschauwer SI; Willems-Widyastuti A; Geenens R; Van Raemdonck DE; Dupont LJ; Verbeken EK; Meyts I
    Am J Respir Crit Care Med; 2011 Apr; 183(8):977-86. PubMed ID: 21097694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine networking of innate immunity cells: a potential target of therapy.
    Striz I; Brabcova E; Kolesar L; Sekerkova A
    Clin Sci (Lond); 2014 May; 126(9):593-612. PubMed ID: 24450743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-27 mediates inflammation during chronic disease.
    Wynick C; Petes C; Gee K
    J Interferon Cytokine Res; 2014 Oct; 34(10):741-9. PubMed ID: 24797503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.
    Taniguchi K; Karin M
    Semin Immunol; 2014 Feb; 26(1):54-74. PubMed ID: 24552665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of IL-15 in gastrointestinal diseases: a bridge between innate and adaptive immune response.
    Pagliari D; Cianci R; Frosali S; Landolfi R; Cammarota G; Newton EE; Pandolfi F
    Cytokine Growth Factor Rev; 2013 Oct; 24(5):455-66. PubMed ID: 23791986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow cytometric detection of type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-5) cytokines in T-helper and T-suppressor/cytotoxic cells in rheumatoid arthritis, allergic asthma and atopic dermatitis.
    Schuerwegh AJ; De Clerck LS; De Schutter L; Bridts CH; Verbruggen A; Stevens WJ
    Cytokine; 1999 Oct; 11(10):783-8. PubMed ID: 10525317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.
    Jones SA; Jenkins BJ
    Nat Rev Immunol; 2018 Dec; 18(12):773-789. PubMed ID: 30254251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRPM channels as potential therapeutic targets against pro-inflammatory diseases.
    Zierler S; Hampe S; Nadolni W
    Cell Calcium; 2017 Nov; 67():105-115. PubMed ID: 28549569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
    Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
    Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate immunity in inflammatory bowel disease: state of the art.
    Hisamatsu T; Ogata H; Hibi T
    Curr Opin Gastroenterol; 2008 Jul; 24(4):448-54. PubMed ID: 18622158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Interleukin-6 Signaling in Clinic.
    Kang S; Tanaka T; Narazaki M; Kishimoto T
    Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.